logo

For the Inventor, By the Inventor

Willowdale, Canada

Mary E Ewasyshyn

This inventor holds 27 USPTO granted patents, primarily in Vaccine Development. Top assignees: Connaught Laboratories Limited, Sanofi Pasteur Inc., Aventis Pasteur Limited. Active years: 1998-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary E Ewasyshyn. Retrieved from https://idiyas.com/inventor/mary-e-ewasyshyn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 27

% Patents Active = 77.8

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 138(Granted Patents)


Location History:

  • Willowdale, CA (1998 - 2007)
  • Thornhill, CA (2000 - 2010)

Company Filing History:

goldMedal13 out of 145 
 
Connaught Laboratories Limited
 patents
silverMedal7 out of 168 
 
Sanofi Pasteur Inc.
 patents
bronzeMedal4 out of 75 
 
Aventis Pasteur Limited
 patents
4. 1 out of 1 
 
Pasteur Merieux Connaught Canada
 patent
5. 1 out of 1 
 
Sanifo Pasteur Limited
 patent
6. 1 out of 834,708 
Other
 patents

Years Active: 1998-2010

Loading Chart...
Areas of Expertise:
Chimeric Immunogens
Respiratory Syncytial Virus
Nucleic Acid Vaccines
Viral Envelope Proteins
Immunization Procedures
Parainfluenza Virus
Hybrid Genes
Inactivated Vaccines
Virus Production
Protein Purification
Infection Detection
Vaccine Protection
27 patents (USPTO):Explore Patents
1. 7671186 - Chimeric immunogens (2010-03-02),
2. 7619063 - Chimeric immunogens (2009-11-17),
3. 7514535 - Chimeric immunogens (2009-04-07),
4. 7498153 - Chimeric immunogens (2009-03-03),
5. 7405273 - Chimeric immunogens (2008-07-29),
6. 7244589 - Chimeric immunogens (2007-07-17),
7. 7223410 - Inactivated respiratory syncytial viral vaccines (2007-05-29),
8. 7083795 - Inactivated respiratory syncytial viral vaccines (2006-08-01),
9. 6677127 - Nucleic acid respiratory syncytial virus vaccines (2004-01-13),
10. 6486135 - Nucleic acid respiratory syncytial virus vaccines (2002-11-26),
11. 6455050 - Production of virus and purfication of viral envelope proteins for vaccine use (2002-09-24),
12. 6395469 - Inactivated respiratory syncytial viral vaccines (2002-05-28),
13. 6306637 - Production of virus and purification of viral envelope proteins for vaccine use (2001-10-23),
14. 6245549 - Production of virus and purification of viral envelope proteins for vaccine use (2001-06-12),
15. 6225091 - Multimeric hybrid gene encoding a chimeric protein which confers protection against parainfluenza virus and respiratory synctial virus (2001-05-01),

Title: **The Innovative Work of Mary E. Ewasyshyn in Immunogen Research**

Introduction

Mary E. Ewasyshyn is a distinguished inventor located in Willowdale, CA, known for his significant contributions to medical research and immunogen technology. With an impressive portfolio of 27 patents, Ewasyshyn has been instrumental in advancing the field of immunology, particularly in developing hybrid genes that can combat viral infections.

Latest Patents

Among his latest achievements are patents related to chimeric immunogens. These multimeric hybrid genes encode chimeric proteins that combine gene sequences from two different pathogens: the parainfluenza virus (PIV) and respiratory syncytial virus (RSV). His innovative work allows for the creation of a single recombinant immunogen capable of providing protection against diseases caused by both PIV and RSV in infants and vulnerable populations.

Career Highlights

Mary E. Ewasyshyn has taken his expertise to major companies, including Connaught Laboratories Limited and Sanofi Pasteur Inc. His work in these renowned organizations has positioned him as a leading figure in the development of vaccines and immunogens that are critical to public health.

Collaborations

Throughout his career, Ewasyshyn has collaborated with several notable professionals in the field. Among his esteemed coworkers are Michel Henri Klein and Run-Pan Du, whose combined expertise has paved the way for groundbreaking advancements in immunogen research.

Conclusion

Mary E. Ewasyshyn's commitment to innovation in immunogen technology positions him as a key contributor to the fight against infectious diseases. Through his patents and collaborations, he continues to support the development of effective vaccines that safeguard the health of vulnerable populations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…